Research study · Regional Anesthesia & Pain Medicine · 2023
Evaluating the impact of cannabinoids on sleep health and pain in patients with chronic neuropathic pain: a systematic review and meta-analysis of randomized controlled trials
Verified on PubMed Systematic review or meta-analysis
A 2023 meta-analysis in Regional Anesthesia & Pain Medicine tested cannabinoids in sleep. Cannabinoids may improve sleep quality in patients with chronic neuropathic pain. This review suggests that while cannabinoids may offer modest sleep benefits for patients with chronic neuropathic pain, their ability to reduce pain is less certain and comes with a higher risk.
In plain language
Study overview
Clinicians should consider the potential benefits of cannabinoids for improving sleep in patients with chronic neuropathic pain, while remaining cautious about the limited evidence for pain relief.
Findings
Cannabinoids may improve sleep quality in patients with chronic neuropathic pain. Limited evidence exists regarding the efficacy of cannabinoids for pain management. Further research is needed to establish optimal dosing and long-term effects.
The deeper readScientific analysis
Background Chronic neuropathic pain is often debilitating and can have a significant impact on sleep health and quality of life. There is limited information on the impact of cannabinoids on sleep health when treating neuropathic pain. Objective The objectives of this systematic review and meta-analysis were to determine the effect of cannabinoids on sleep quality, pain intensity, and patient impression of treatment efficacy in patients with neuropathic pain. Evidence review Nine available medical literature databases were searched for randomized controlled trials comparing synthetic and natural cannabinoids to placebo in patients with neuropathic pain syndromes. Data on validated tools for sleep quality, pain intensity, patients' global impression of change (PGIC), and incidence of adverse effects of cannabinoids were extracted and synthesized. Findings Of the 3491 studies screened, eight randomized controlled trials satisfied the inclusion criteria for this review. Analyses were performed using R-4.1.2. using the metafor package and are interpreted using alpha=0.05 as the threshold for statistical significance. Validated measures for sleep health were not used in most studies. Meta-analysis of data from six studies showed that cannabinoids were associated with a significant improvement in sleep quality (standardized mean difference (SMD): 0.40; 95% CI: 0.19 to -0.61, 95% prediction interval (PI): -0.12 to 0.88, p-value=0.002, I2=55.26, tau^2=0.05, Q-statistic=16.72, GRADE: moderate certainty). Meta-analysis of data from eight studies showed a significant reduction in daily pain scores in the cannabinoid (CB) group (SMD: -0.55, 95% CI: -0.69 to -0.19, 95% PI: -1.51 to 0.39, p=0.003, I2=82.49, tau^2=0.20, Q-statistic=47.69, GRADE: moderate certainty). However, sleep health and analgesic benefits were associated with a higher likelihood of experiencing daytime somnolence, nausea, and dizziness. Conclusions Cannabinoids have a role in treating chronic neuropathic pain as evidenced by significant improvements in sleep quality, pain intensity, and PGIC. More research is needed to comprehensively evaluate the impact of cannabinoids on sleep health and analgesic efficacy.
The paper
Citation
McParland AL, Bhatia A, Matelski J, Tian C, Diep C, Clarke H, et al. Evaluating the impact of cannabinoids on sleep health and pain in patients with chronic neuropathic pain: a systematic review and meta-analysis of randomized controlled trials. Regional Anesthesia & Pain Medicine (2023). PubMed 36598058 · DOI
Limitations the authors noted
Lack of validated tools for sleep health in most included primary studies. Absence of objective sleep measurements such as actigraphy or polysomnography. No studies investigated pre-existing sleep disorders like sleep apnea. Concomitant medications such as opioids and gabapentinoids were permitted and varied across trials.
In practice
Why this matters
This review suggests that while cannabinoids may offer modest sleep benefits for patients with chronic neuropathic pain, their ability to reduce pain is less certain and comes with a higher risk of side effects like drowsiness.
Browse related research
Condition: Chronic pain Condition: Neuralgia Condition: Sleep Topic: Analgesics Topic: Cannabinoids
Related on CED Clinic
Back to Daily Research and Patient Questions
Reviewed by Dr. Caplan on September 24, 2026.
This page is general education about a published study. It is not medical advice and does not create a doctor-patient relationship. For care specific to you, book a consultation.